Market Spotlight: Melanoma Disease Coverage
Disease Overview
The World Health Organization has reported that the incidence of melanoma is increasing
faster than that of any other cancer in the world. Melanoma occurs when melanocytes –
melanin-producing cells – become malignant. Malignancy of melanocytes in the basal layer
of the skin is referred to as primary cutaneous malignant melanoma. Unlike many other
common cancers, there is no significant increase in risk for the elderly; instead, the increase
in incidence is likely to be due to changes in lifestyle. In particular, the amount of and
susceptibility to ultraviolet exposure are key risk factors for malignant melanoma, and are
driving the increase in incidence in all age groups.
Market Snapshot
Immunotherapy monotherapies and combination therapies will be the main drivers of
growth in the melanoma market over the forecast period.
The introduction of targeted therapies has substantially changed the treatment landscape of
melanoma.
Melanoma is a common cancer in the Western world with an increasing incidence, although
prognosis is highly variable.
Immune checkpoint inhibitors Yervoy, Opdivo, and Keytruda will be key drivers of growth in
the melanoma market.
New developers are targeting NRAS and BRAF mutation-positive patients to distinguish their
products, despite the market being limited.
Immunotherapies are changing melanoma treatment paradigms.
Exclusive Sample Report @
https://www.reportsworldwide.com/enquiry?report_id=42610
Major TOC Market:
1 FORECAST: MELANOMA
2 Executive Summary
3 Market Overview and Trends
4 Market Definition and Methodology
5 binimetinib
6 Cotellic (cobimetinib)
7 encorafenib
8 Imlygic (talimogene laherparepvec)
9 Keytruda (pembrolizumab)
10 Mekinist (trametinib)
11 Opdivo (nivolumab)
12 Tafinlar (dabrafenib)
13 Yervoy (ipilimumab)
14 Zelboraf (vemurafenib)
15 Primary Research Methodology